Prescribing information



What is the injection of LUCENTIS® (ranibizumab) for?

Adults: the treatment of neovascular (wet) age-related macular degeneration (AMD), the treatment of visual impairment due to diabetic macular oedema (DMO), the treatment of proliferative diabetic retinopathy (PDR), the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (brand RVO or central RVO), the treatment of visual impairment due to choroidal neovascularisation (CNV).
Preterm infants: The treatment of retinopathy of prematurity (ROP) with zone 1 (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

Resources for your patients:

Preview image. Your Guide to Lucentis booklet for patients.

Your guide to LUCENTIS

A booklet for patients who have been prescribed LUCENTIS containing information about LUCENTIS, how it is administered and which side effects to look out for.


Preview image. LUCENTIS parent/guardian booklet (ROP).

LUCENTIS parent/guardian booklet (ROP)

A leaflet on retinopathy of prematurity (ROP) for parents of infants who are receiving treatment with LUCENTIS.





  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics.
Rate this content: 
Average: 4.3 (3 votes)
UK | September 2023 | 285827

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]